Maggie L. Shaw

A new approach to identifying and defining heart failure among patients with chronic obstructive pulmonary disease (COPD) involves combining information gleaned from reviewing their electronic medical records and examination charts.

In an abstract presented at this year’s American Academy of Neurology annual meeting, patients with multiple sclerosis (MS) taking ocrelizumab had less of an immune reaction to infection with SARS-CoV-2, the virus that causes COVID-19.

With persons living with HIV increasingly succumbing to age-related diseases, a group of investigators looked into the greater risk of coronary artery disease among these individuals.

Overweight and obese adults, whose body mass index trended upward in a recent UK study, had higher risk of heart failure, all-cause mortality, and cardiovascular disease–related mortality.

Compared with disease-modifying therapy (DMT), age, insurance status, and Hispanic ethnicity were shown to more accurately predict likelihood of COVID-19 and hospitalization from it among individuals with multiple sclerosis (MS).

This recent study out of Japan compared the use of renin-angiotensin system inhibitors and β-blockers among patients with heart failure, both those who had physical limitations and those who did not.

Elevated levels of 2 inflammatory biomarkers may indicate a greater heart failure hospitalization risk for patients who have diagnosed atrial fibrillation.

This is a case study of a male patient with Fabry disease who presented with severe anaphylaxis following re-initiation of full-strength treatment with intravenous agalsidase beta (Fabrazyme).

A prospective bicentric cohort study among individuals with relapsing-remitting multiple sclerosis (RRMS) showed that 32% developed at least 1 skin-related adverse reaction following cladribine administration.

Previous studies have investigated the association between hot flashes and immune system activation among women with HIV, but this is the first study to investigate an additional link to adverse subclinical cardiac pathology.

The advent of both new diagnostic criteria and treatments have necessitated a reevaluation of fatigue among individuals who have multiple sclerosis, investigators say.

On day 2 of this year’s Community Oncology Conference, a panel of government and health policy experts gathered to discuss the hot-button issue of political influence on cancer policy and the damage community oncology has suffered this past year.

There are many sources, and definitions, of where the value in cancer care lies. In this panel discussion, a cancer survivor and patient advocate, an oncologist, and a benefits professional provided their perspectives on what value in cancer care means to them.

A popular misconception of palliative care is that it only has importance toward making patients comfortable at the end of their lives, noted a palliative care physician on the first day of the 2021 Community Oncology Conference, presented by the Community Oncology Alliance.

Day 1 of this year’s virtual Community Oncology Conference opened with a panel discussion that touched on all things related to the COVID-19 pandemic, with leaders presenting a unified front.

A higher risk of adult-onset heart failure was found in this Swedish study that investigated its association with singleton live births before 37 weeks gestation.

A recent subgroup analysis of the DAPA-HF study investigated possible clinical outcome differences between women and men following the addition of dapagliflozin to their treatment regimens.

Among patients with multiple sclerosis, there is a 16% greater risk of infection, including for lower respiratory and herpes virus infections, after administration of fingolimod.

Morbidity and mortality in individuals younger than 55 years with heart failure may be attenuated by targeting possible age-dependent risk factors

This feature is the first in a 6-part series on individuals and international organizations working to bring local and global awareness to the ongoing HIV/AIDS epidemic, which is marking its 40th anniversary this year.

With most current therapies for patients with multiple sclerosis (MS) targeting disease progression, a recent review evaluated transcranial direct current stimulation’s ability to improve certain disease symptoms.

Investigators aimed to close the knowledge gap on interindividual variability in cognitive evaluation outcomes by considering both cognitive impairment and mood disorders to better prediction accuracy.

A substantially higher risk of anal carcinoma following the development of anogenital warts was seen among adults living with HIV and being treated in Washington, DC.

After a 12-month follow-up of patients in the CHAMP-HF registry, Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ-OS) was shown to be more prognostically accurate compared with New York Heart Association functional class.

With many patients with multiple sclerosis (MS) increasingly turning to herbal drugs and supplements to treat their disease, for which there is no cure, a recent review evaluated the safety of these alternative therapies.

Rates of hepatocellular carcinoma were highest among persons living with HIV who have higher RNA levels, lower CD4 cell counts, or used injection drugs.

Among patients with atrial fibrillation (AFib) in the RATE-AF trial, the index-beat approach produced superior results on a potential diagnosis of heart failure vs consecutive-beat methods.

Reduced left ventricular ejection fraction, longitudinal strain, and circumferential strain have possibly been linked to development of heart failure among elderly individuals.

Among these factors, having a higher degree of disability from multiple sclerosis (MS) was independently associated with higher morbidity and mortality risks from having a comorbid case of COVID-19.

Despite HHS’ recommendation that everyone with HIV start antiretroviral therapy (ART) soon after their diagnosis, uptick disparities remain and are especially apparent among persons with drug abuse or dependence.